What we know so far
Another Heart Drug Fails, Shocking Cardiologists The New York Times Novartis’ experimental cardiovascular drug fails a pivotal study STAT Novartis Drug Fails Key Test for New Heart Disease Approach Bloomberg.com Ionis partner Novartis announces Lp(a)HORIZON Phase 3 topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD) Business Wire Novartis announces Lp(a)HORIZON Phase III topline results GlobeNewswire Another Heart Drug Fails, Shocking Cardiologists The New York Times Novartis’ experimental cardiovascular drug fails a pivotal study STAT Novartis Drug Fails Key Test for New Heart Disease Approach Bloomberg.com Ionis partner Novartis announces Lp(a)HORIZON Phase 3 topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD) Business Wire Novartis announces Lp(a)HORIZON Phase III topline results GlobeNewswire
Why this story matters
This business story is being watched because it can affect readers, markets, or public policy in the hours after it breaks. The New York Times was among the first outlets to surface the report. YuToday writes an original briefing around the confirmed facts instead of reprinting another outlet’s article.
The latest reporting
Reported context includes the following: Another Heart Drug Fails, Shocking Cardiologists The New York Times Novartis’ experimental cardiovascular drug fails a pivotal study STAT Novartis Drug Fails Key Test for New Heart Disease Approach Bloomberg.com Ionis partner Novartis announces Lp(a)HORIZON Phase 3 topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD) Business Wire Novartis announces Lp(a)HORIZON Phase III topline results GlobeNewswire Another Heart Drug Fails, Shocking Cardiologists The New York Times Novartis’ experimental cardiovascular drug fails a pivotal study STAT Novartis Drug Fails Key Test for New Heart Disease Approach Bloomberg.com Ionis partner Novartis announces Lp(a)HORIZON Phase 3 topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD) Business Wire Novartis announces Lp(a)HORIZON Phase III topline results GlobeNewswire
How YuToday is covering it
The newsroom gathers the confirmed facts, writes a structured briefing with takeaways and common questions, and credits the originating outlet. That keeps the page useful for readers who want the story in one place.
What happens next
Watch for official statements, follow-up data, and confirmation from a second independent outlet. YuToday will refresh this briefing when new facts appear.
